Discriminatory practices by a health benefit plan issuer, pharmacy benefit manager, and third-party payor and certain prescription drug manufacturers, distributors, and related persons with respect to certain entities participating in a federal drug discount program; providing a civil penalty

Texas House Bill 3265 (HB3265) aims to prevent discriminatory practices by health insurers, pharmacy benefit managers, third-party payors, and certain prescription drug manufacturers and distributors against healthcare providers participating in the federal 340B Drug Pricing Program. This program allows eligible healthcare providers to purchase outpatient drugs at reduced prices to serve underserved communities. The bill prohibits these entities from engaging in practices that would undermine the benefits of the 340B program for these providers and imposes civil penalties for violations.

Supporters of HB3265 argue that the bill is essential for protecting the integrity of the 340B Drug Pricing Program, which has been instrumental in enabling healthcare providers to offer affordable medications and services to underserved populations in Texas. By preventing discriminatory practices, the bill ensures that the cost savings intended by the 340B program reach the patients who need them most.

Critics of HB3265 contend that the bill could lead to increased regulatory burdens on health insurers and pharmaceutical companies, potentially resulting in higher administrative costs. They also express concern that the legislation might interfere with existing contractual agreements and could lead to unintended consequences in the healthcare market.